vida: extract claims from 2026-04-22-npr-glp1-coverage-decline-insurance-slipping-2026

- Source: inbox/queue/2026-04-22-npr-glp1-coverage-decline-insurance-slipping-2026.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-employer-coverage-declining-despite-utilization-growth-creating-access-gap.md

@@ -46,3 +46,10 @@ The FDA's April 2026 clarification targeted combination formulations (semaglutid
 **Source:** KFF 2025, Mercer 2026, DistilINFO via NPR
 
 Reconciliation of apparent contradiction: KFF shows 49% large employer coverage (up from 44%), Mercer shows 90% large employer retention, yet DistilINFO confirms 22% decline in total covered lives. The resolution: large employers (500+) are stable/expanding while smaller employers, health systems, state plans, and regional payers withdraw coverage. The net effect is population-level coverage decline despite large-employer stability. This confirms the bifurcation pattern where employer size predicts coverage persistence.
+
+
+## Supporting Evidence
+
+**Source:** NPR April 22, 2026; Mercer 2026
+
+NPR provides second-source confirmation of the covered lives decline: 3.6M (2024) → 2.8M (2026), a 22% drop. Multiple employers in NPR focus groups reported firms 'will no longer cover GLP-1 agonists for weight loss.' The Mercer data shows 66% of employers say GLP-1 had 'significant' impact on prescription drug spending, and 77% of large employers prioritize managing GLP-1 costs. This confirms the access gap is widening despite clinical demand growth.

domains/health/glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-04-23-icer-glp1-affordable-access-2025.md
 scope: structural
 sourcer: ICER
 supports: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medicaid-glp1-coverage-reversing-through-state-budget-pressure"]
-related: ["glp-1-receptor-agonists-are-the-largest-therapeutic-category-launch-in-pharmaceutical-history-but-their-chronic-use-model-makes-the-net-cost-impact-inflationary-through-2035", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "glp1-behavioral-mandate-rate-tripled-2024-2025-signaling-managed-access-infrastructure-shift"]
+related: ["glp-1-receptor-agonists-are-the-largest-therapeutic-category-launch-in-pharmaceutical-history-but-their-chronic-use-model-makes-the-net-cost-impact-inflationary-through-2035", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "glp1-behavioral-mandate-rate-tripled-2024-2025-signaling-managed-access-infrastructure-shift", "glp1-employer-coverage-declining-despite-utilization-growth-creating-access-gap"]
 ---
 
 # GLP-1 obesity coverage creates acute payer fiscal crisis with employer plans experiencing >10x PMPM cost increases in 2023-2024 and major insurers reporting operating losses driven primarily by GLP-1 expenditures
@@ -38,3 +38,10 @@ Evernorth EncircleRx reports ~$200 million saved since 2024 across 9 million enr
 **Source:** DistilINFO April 2026
 
 Blue Cross Blue Shield Michigan reported $350M increase in GLP-1 drug costs in 2023 alone. Blue Cross Blue Shield Massachusetts reported $400M operating loss in 2024 driven largely by GLP-1 spending. These are major regional Blues plans with broad population coverage, confirming the fiscal unsustainability is affecting diverse payer types, not just large employers.
+
+
+## Supporting Evidence
+
+**Source:** NPR April 22, 2026; Mercer 2026
+
+One employer in the NPR article reported GLP-1 weight-loss spending increasing 50% year over year, corroborating the fiscal unsustainability finding. Mercer reports 59% of the largest employers (5,000+ workers) say GLP-1 costs exceeded expectations, and 66% report 'significant' impact on prescription drug spending. This confirms the cost trajectory is forcing payer responses.

domains/health/mhpaea-enforcement-closes-coverage-gaps-but-not-access-gaps-because-payers-differentially-treat-mental-health-versus-medical-reimbursement-rates.md

@@ -85,4 +85,4 @@ National Index launch confirms the two-level access problem is structural and ne
 
 **Source:** EBSA 4th MHPAEA Report, 2025-2026
 
-The 4th MHPAEA Report documented payers actively raising M/S reimbursement to fix network gaps while NOT applying the same methodology to MH networks, providing direct evidence of differential treatment mechanism. This shows the gap is not passive neglect but active policy divergence.
+The 4th MHPAEA Report documented payers actively raising M/S reimbursement to fix network gaps while NOT applying the same methodology to MH networks, providing direct evidence of differential treatment mechanism. This shows the gap is not passive neglect but active policy divergence.

inbox/archive/health/2026-04-22-npr-glp1-coverage-decline-insurance-slipping-2026.md

@@ -7,10 +7,13 @@ date: 2026-04-22
 domain: health
 secondary_domains: []
 format: thread
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-01
 priority: high
 tags: [GLP-1, obesity, employer-coverage, covered-lives, insurance-access, cost-crisis, Wegovy, Zepbound]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content